CL2013001497A1 - Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis. - Google Patents
Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis.Info
- Publication number
- CL2013001497A1 CL2013001497A1 CL2013001497A CL2013001497A CL2013001497A1 CL 2013001497 A1 CL2013001497 A1 CL 2013001497A1 CL 2013001497 A CL2013001497 A CL 2013001497A CL 2013001497 A CL2013001497 A CL 2013001497A CL 2013001497 A1 CL2013001497 A1 CL 2013001497A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical preparation
- aine
- sprains
- bruises
- rheumatism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010052847A DE102010052847A1 (de) | 2010-11-29 | 2010-11-29 | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001497A1 true CL2013001497A1 (es) | 2013-12-27 |
Family
ID=45047786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001497A CL2013001497A1 (es) | 2010-11-29 | 2013-05-27 | Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130266658A1 (es) |
| EP (1) | EP2645996B1 (es) |
| CN (1) | CN103260607B (es) |
| BR (1) | BR112013013042B1 (es) |
| CA (1) | CA2819039C (es) |
| CL (1) | CL2013001497A1 (es) |
| CO (1) | CO6801720A2 (es) |
| CY (1) | CY1117589T1 (es) |
| DE (1) | DE102010052847A1 (es) |
| DK (1) | DK2645996T3 (es) |
| EA (1) | EA025070B1 (es) |
| EC (1) | ECSP13012715A (es) |
| ES (1) | ES2574402T3 (es) |
| HR (1) | HRP20160593T1 (es) |
| HU (1) | HUE027418T2 (es) |
| MX (1) | MX346789B (es) |
| PL (1) | PL2645996T3 (es) |
| RS (1) | RS54826B1 (es) |
| SI (1) | SI2645996T1 (es) |
| SM (1) | SMT201600285B (es) |
| WO (1) | WO2012072570A2 (es) |
| ZA (1) | ZA201303568B (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877085B (zh) * | 2013-10-16 | 2016-05-04 | 山西兰花药业有限公司 | 酮洛芬奥美拉唑缓释微丸及其制备方法 |
| US10729773B2 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933136B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11045549B2 (en) | 2015-02-10 | 2021-06-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10722583B2 (en) | 2015-02-10 | 2020-07-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10695429B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758618B2 (en) | 2015-02-10 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10780166B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10799588B2 (en) | 2015-02-10 | 2020-10-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10058614B2 (en) | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11602563B2 (en) | 2015-02-10 | 2023-03-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10537642B1 (en) | 2015-02-10 | 2020-01-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10512692B2 (en) | 2015-02-10 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10780165B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10517950B1 (en) | 2015-02-10 | 2019-12-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11738085B2 (en) | 2015-02-10 | 2023-08-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11607456B2 (en) | 2015-02-10 | 2023-03-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10702602B2 (en) | 2015-02-10 | 2020-07-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10653777B2 (en) | 2015-02-10 | 2020-05-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10821181B2 (en) | 2015-02-10 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11013805B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729774B1 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11110173B2 (en) | 2015-02-10 | 2021-09-07 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US10695430B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10532101B1 (en) | 2015-02-10 | 2020-01-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933137B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11013806B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US9821075B2 (en) | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| JP6622285B2 (ja) * | 2015-03-16 | 2019-12-18 | 宇部マテリアルズ株式会社 | 酸化マグネシウム粉末及びこれを含む樹脂組成物並びに酸化マグネシウム粉末の製造方法 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| EP3117824A1 (en) * | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| BE1024339B1 (fr) * | 2016-07-01 | 2018-01-29 | Be Pharbel Mfg Sa | Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide |
| EP3324948B1 (en) | 2015-07-17 | 2023-02-15 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10471014B2 (en) | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11266657B2 (en) | 2017-01-04 | 2022-03-08 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11207327B2 (en) | 2017-01-04 | 2021-12-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10940153B2 (en) | 2017-01-04 | 2021-03-09 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729697B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10821182B2 (en) | 2017-06-29 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10583144B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433079B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11806354B2 (en) | 2017-01-04 | 2023-11-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10583088B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11801250B2 (en) | 2017-01-04 | 2023-10-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433078B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10905693B2 (en) | 2017-01-04 | 2021-02-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11471465B2 (en) | 2017-01-04 | 2022-10-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| HUE052749T2 (hu) | 2017-01-04 | 2021-12-28 | Axsome Therapeutics Inc | Meloxicamot és rizatriptant tartalmazó gyógyászati készítmények |
| US10729696B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10561664B1 (en) | 2017-01-04 | 2020-02-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10894053B2 (en) | 2017-01-04 | 2021-01-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617755B2 (en) | 2017-01-04 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11219626B2 (en) | 2017-06-29 | 2022-01-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11759522B2 (en) | 2017-06-29 | 2023-09-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10987358B2 (en) | 2017-06-29 | 2021-04-27 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10918722B2 (en) | 2017-06-29 | 2021-02-16 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11865117B2 (en) | 2017-06-29 | 2024-01-09 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11510927B2 (en) | 2017-06-29 | 2022-11-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758617B2 (en) | 2017-06-29 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11185550B2 (en) | 2017-06-29 | 2021-11-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10688185B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10688102B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Combination treatment for migraine and other pain |
| US11617756B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10512693B2 (en) | 2017-06-29 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US20190125676A1 (en) * | 2017-11-02 | 2019-05-02 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors for oral administration |
| CN109700777B (zh) * | 2019-02-27 | 2021-06-22 | 中国药科大学 | 一种pH依赖型药物疏水骨架缓释片及其制备方法 |
| IL293653A (en) * | 2019-12-11 | 2022-08-01 | Evonik Operations Gmbh | Dosage form for use in the treatment or prevention of disease |
| CA3160869A1 (en) | 2019-12-11 | 2021-06-17 | Priyanka HAKSAR | Dosage form for use in treating or preventing of a disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| DE19626045C2 (de) * | 1996-06-28 | 1998-12-03 | Klinge Co Chem Pharm Fab | Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben |
| US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| SE0200895D0 (sv) * | 2002-03-22 | 2002-03-22 | Astrazeneca Ab | New pharmaceutical composition |
| AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
| EP1833469A2 (en) * | 2005-01-03 | 2007-09-19 | Lupin Ltd. | Pharmaceutical composition of acid labile substances |
-
2010
- 2010-11-29 DE DE102010052847A patent/DE102010052847A1/de not_active Withdrawn
-
2011
- 2011-11-28 CN CN201180057095.5A patent/CN103260607B/zh active Active
- 2011-11-28 BR BR112013013042-3A patent/BR112013013042B1/pt active IP Right Grant
- 2011-11-28 MX MX2013005896A patent/MX346789B/es active IP Right Grant
- 2011-11-28 DK DK11788458.5T patent/DK2645996T3/en active
- 2011-11-28 ES ES11788458.5T patent/ES2574402T3/es active Active
- 2011-11-28 CA CA2819039A patent/CA2819039C/en active Active
- 2011-11-28 SI SI201130835A patent/SI2645996T1/sl unknown
- 2011-11-28 HU HUE11788458A patent/HUE027418T2/en unknown
- 2011-11-28 WO PCT/EP2011/071149 patent/WO2012072570A2/de active Application Filing
- 2011-11-28 RS RS20160387A patent/RS54826B1/sr unknown
- 2011-11-28 EA EA201390793A patent/EA025070B1/ru not_active IP Right Cessation
- 2011-11-28 PL PL11788458T patent/PL2645996T3/pl unknown
- 2011-11-28 EP EP11788458.5A patent/EP2645996B1/de active Active
-
2013
- 2013-05-16 ZA ZA2013/03568A patent/ZA201303568B/en unknown
- 2013-05-27 CL CL2013001497A patent/CL2013001497A1/es unknown
- 2013-05-28 CO CO13130481A patent/CO6801720A2/es not_active Application Discontinuation
- 2013-05-29 US US13/904,924 patent/US20130266658A1/en not_active Abandoned
- 2013-06-24 EC ECSP13012715 patent/ECSP13012715A/es unknown
-
2016
- 2016-06-01 CY CY20161100484T patent/CY1117589T1/el unknown
- 2016-06-01 HR HRP20160593TT patent/HRP20160593T1/hr unknown
- 2016-08-25 SM SM201600285T patent/SMT201600285B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160593T1 (hr) | 2016-07-29 |
| EP2645996B1 (de) | 2016-03-02 |
| EP2645996A2 (de) | 2013-10-09 |
| BR112013013042B1 (pt) | 2021-09-28 |
| RS54826B1 (sr) | 2016-10-31 |
| BR112013013042A2 (pt) | 2016-08-09 |
| US20130266658A1 (en) | 2013-10-10 |
| MX2013005896A (es) | 2013-06-28 |
| WO2012072570A3 (de) | 2012-09-13 |
| DE102010052847A1 (de) | 2012-05-31 |
| ES2574402T3 (es) | 2016-06-17 |
| EA025070B1 (ru) | 2016-11-30 |
| DK2645996T3 (en) | 2016-06-13 |
| CA2819039C (en) | 2018-09-11 |
| WO2012072570A2 (de) | 2012-06-07 |
| MX346789B (es) | 2017-03-31 |
| SMT201600285B (it) | 2016-11-10 |
| EA201390793A1 (ru) | 2013-11-29 |
| PL2645996T3 (pl) | 2016-08-31 |
| ECSP13012715A (es) | 2013-08-30 |
| SI2645996T1 (sl) | 2016-07-29 |
| CN103260607A (zh) | 2013-08-21 |
| CA2819039A1 (en) | 2012-06-07 |
| CO6801720A2 (es) | 2013-11-29 |
| CY1117589T1 (el) | 2017-04-26 |
| HUE027418T2 (en) | 2016-09-28 |
| CN103260607B (zh) | 2016-05-04 |
| ZA201303568B (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001497A1 (es) | Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis. | |
| GT201500105A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| SG11201602070TA (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| CL2015001891A1 (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014). | |
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| CL2016000530A1 (es) | Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13). | |
| CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| BR112012004970A2 (pt) | inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer | |
| ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
| CO6842016A2 (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| BRPI1016147A2 (pt) | sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino | |
| EP4292550A3 (en) | Anchor delivery system | |
| ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| EA201691193A1 (ru) | Система доставки лекарственных средств | |
| CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
| CO6811867A2 (es) | Cannabinoides para uso en el tratamiento del dolor neuropático | |
| ECSP12011735A (es) | Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor | |
| BR112012028773A2 (pt) | composições farmacêuticas compreendendo hidromorfona e naloxona | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| WO2012097264A3 (en) | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof | |
| CL2016001510A1 (es) | Células madre derivadas de musculo de mamifero | |
| CL2012003209A1 (es) | Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. |